CADLCandel Therapeutics, Inc.

Healthcare
$9.66+72% 1Y

The financials

Candel Therapeutics, Inc. by the numbers

The next results filing is expected around Nov 12, 2026, the same week as a year ago.

Candel Therapeutics, Inc. income statement, Q2 2026 against the same quarter a year earlier
Income statementQ2 2026Q2 2025Change
Operating income−$27M−$11Mn/a
Net income−$39M−$4.8Mn/a
Diluted EPS−$0.52−$0.09n/a

Biotechnology

Ranks #117 of 196 by RyuScore

Compare peers
AVTX-1.1%
Avalo Therapeutics, Inc.
VSTM-1.8%
Verastem, Inc.
DSGN-1.8%
Design Therapeutics, Inc.
MDXG+0.22%
MIMEDX GROUP, INC.
PHAR-2.6%
Pharming Group N.V.
OLMA-1.5%
Olema Pharmaceuticals, Inc.